Article
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
Blood - 26 Sept 2013
Baur Andreas S, Lutz Manfred B, Schierer Stephan, Beltrame Luca, Theiner Gabi, Zinser Elisabeth, Ostalecki Christian, Heidkamp Gordon, Haendle Ina, Erdmann Michael, Wiesinger Manuel, Leisgang Waltraud, Gross Stefanie, Pommer Ansgar J, Kämpgen Eckhart, Dudziak Diana, Steinkasserer Alexander, Cavalieri Duccio, Schuler-Thurner Beatrice, Schuler Gerold
Abstract excerpt
Denileukin diftitox (DD), a diphtheria toxin fragment IL-2 fusion protein, is thought to target and kill CD25(+) cells. It is approved for the treatment of cutaneous T-cell lymphoma and is used experimentally for the depletion of regulatory T cells (Treg) in cancer trials. Curiously enough, clini...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.